Longeveron, Inc. (LGVN)
2.435
-0.04
(-1.81%)
USD |
NASDAQ |
Oct 12, 15:55
Longeveron Profit Margin (Quarterly) : -2.12K% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.12K% |
| March 31, 2026 | -1.19K% |
| December 31, 2025 | -1.49K% |
| September 30, 2025 | -5.27K% |
| June 30, 2025 | -1.59K% |
| March 31, 2025 | -1.32K% |
| December 31, 2024 | -676.8% |
| September 30, 2024 | -571.7% |
| June 30, 2024 | -729.3% |
| March 31, 2024 | -740.5% |
| December 31, 2023 | -9.57K% |
| September 30, 2023 | -3.40K% |
| June 30, 2023 | -2.60K% |
| Date | Value |
|---|---|
| March 31, 2023 | -1.67K% |
| December 31, 2022 | -3.68K% |
| September 30, 2022 | -1.98K% |
| June 30, 2022 | -1.21K% |
| March 31, 2022 | -948.6% |
| December 31, 2021 | -1.95K% |
| September 30, 2021 | -2.09K% |
| June 30, 2021 | -1.02K% |
| March 31, 2021 | -827.4% |
| December 31, 2020 | -114.9% |
| September 30, 2020 | -50.29% |
| December 31, 2019 | -25.70% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -214.5% |
| Return on Assets | -148.1% |
| Return on Invested Capital | -198.9% |
| Gross Profit Margin (Quarterly) | -13.59% |
| Operating Margin (Quarterly) | -2.15K% |
| Return on Net Operating Assets | -493.9% |